Parker, Alan - Cardiff University

个人简介

My interest in gene and cell therapy began whilst studying for my undergraduate degree in Genetics (University of Sheffield), which inspired me to pursue a PhD in this field. My PhD was performed under the supervision of Prof Len Seymour (now at the University of Oxford) at the university of Birmingham, and I completed my thesis entitled "Development of Peptide Targeted Gene Delivery Systems) in 2003. My first postdoctoral position was under the supervision of Prof John Fabre, where I developed novel bio response peptide systems for local gene delivery (2003-2005) and I published several articles from this post. Whilst in this position I also developed a versatile, highly organised form of nanoparticle (now patent protected) for rapid, targetable delivery of drugs or mRNA/miRNAs into the cytoplasm of target cells (Collins L, Parker AL et al, ACS Nano, 2010). My desire to work on viral vectors for gene and cell therapy applications resulting in my relocating to Glasgow University from 2005-2013, where I made seminal contributions to how Adenoviral (Ad) based vectors interact with host cells and proteins, and how these interactions dictate viral tropism and toxicity. In 2007 I was awarded a prestigious RSE Personal Fellowship to generate safer and more efficacious Ad based vectors for in vivo applications. In 2010-2013 I was a BHF funded Senior Scientist. During this period I published a number of high impact articles (Cell, Blood, PLoS pathogens, Molecular Therapy, Journal of Virology), and patented the use of a novel Ad serotype for gene therapy applications. In 2013 my desire to apply my adenoviral knowledge in the cancer setting resulted in my relocation to Cardiff University as a Lecturer and group leader. In 2014 I was promoted to Senior Lecturer, and my group is now becoming established within the Division of Cancer and Genetics.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Robertson, S.et al. 2016. Retargeting FX binding-ablated HAdV-5 to vascular cells by inclusion of the RGD-4C peptide in hexon hypervariable region 7 and the HI loop. Journal of General Virology 97(8), pp. 1911-1916. (10.1099/jgv.0.000505) pdf Hulin-Curtis, S.et al. 2016. Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy. Cancer Gene Therapy 23(7), pp. 229-234. (10.1038/cgt.2016.22) pdf Uusi-Kerttula, H.et al. 2016. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget 7(19), pp. 27926-27937. (10.18632/oncotarget.8545) pdf Uusi-Kerttula, H.et al. 2015. Oncolytic adenovirus: strategies and insights for vector design and immuno-oncolytic applications. Viruses 7(11), pp. 6009-6042. (10.3390/v7112923) pdf Uusi-Kerttula, H.et al. 2015. Incorporation of alpha v beta 6 integrin-targeting peptide into chimaeric Ad5/fibre knob 48 vector results in efficient tumour-targeting and evasion of neutralisation in clinical ascites [Abstract]. Human Gene Therapy 26(10), pp. A93-A93. (10.1089/hum.2015.29008.abstracts.) Hulin-Curtis, S.et al. 2015. Evaluation of CD46 utilising adenoviral vectors for clinical ovarian cancer applications [Abstract]. Human Gene Therapy 26(9), pp. A33-A34. Uusi-Kerttula, H.et al. 2015. Modulation of Ad5 fibre knob as a means of circumventing pre-existing immunity in clinical ovarian ascites [Abstract]. Human Gene Therapy 26(9), pp. A23-A23. (10.1089/hum.2015.29005.abstracts.) Uusi-Kerttula, H.et al. 2015. Development of an Ad5 vector pseudotyped with Ad48 knob protein and targeted to alpha v beta 6 integrin efficiently targets tumour cells and evades pre-existing immunity in clinical ascites [Abstract]. Human Gene Therapy 26(9), pp. A33-A33. (10.1089/hum.2015.29005.abstracts) Uusi-Kerttula, H.et al. 2015. Incorporation of peptides targeting EGFR and FGFR1 into the adenoviral fibre knob domain, and their evaluation as targeted cancer therapies.. Human Gene Therapy 26(5), pp. 320-329. (10.1089/hum.2015.015) pdf Dakin, R.et al. 2015. Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector. Human Gene Therapy 26(5), pp. 312-319. (10.1089/hum.2015.019) pdf